The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
New National Cholesterol Education Program III Guidelines for Primary Prevention Lipid-Lowering Drug Therapy: Projected Impact on the Size, Sex, and Age Distribution of the Treatment-Eligible Population
Open accessAbstract
Background — The guidelines in the Third Report of the National Cholesterol Education Program (NCEP III) include absolute risk and lower LDL cholesterol (LDL-C) levels to assess eligibility for lipid-lowering drug therapy. We studied the impact of these changes on the size, sex, and age distribution of the target US population using data from the Third Annual National Health and Nutrition Survey (NHANES III) (1988 to 1994). Methods and Results — A subsample of NHANES III participants aged 20 to 79 years with known cardiovascular risk factors and LDL-C levels was identified (n=13 589). We assessed their eligibility for drug therapy first using NCEP II guidelines and then using the new NCEP III criteria. We also calculated the number eligible for LDL-C lowering to <100 mg/dL. An estimated 15 million individuals aged 20 to 79 years are eligible for drug therapy under NCEP II; 51% are males, 49% are females, 26% are <45 years old, and 28% are ≥65 years old. Under NCEP III, 36 million would be eligible for treatment; 55% are males, 45% are females, 32% are <45 years old, and 27% are ≥65 years old. This represents a 140% increase in eligibility overall, a 157% increase among males, a 122% increase among females, a 131% increase among those ≥65 years old, and a 201% increase among those <45 years old. Of treatment-eligible individuals, 26% of males, 24% of females, 39% of elderly, and 14% of those <45 years old are targeted for LDL-C lowering to <100 mg/dL. Conclusions — The NCEP III guidelines will alter the age and sex distributions of the treatment-eligible population, targeting many more younger (<45 years old) and greater numbers of elderly (≥65 years) individuals, particularly for aggressive intervention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prediction of coronary heart disease using risk factor categories
Wilson, P. W. F., D’Agostino, R. B., Levy, D., Belanger, A. M., Silbershatz, H., & Kannel, W. B. (1998) · Circulation · doi:10.1161/01.cir.97.18.1837 · Cited by 9,581
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Second Joint Task Force of European (1998) · European Heart Journal · doi:10.1053/euhj.1998.1243 · Cited by 1,131
Cited by
Long-term persistence in use of statin therapy in elderly patients
Benner, J. S. (2002) · JAMA · doi:10.1001/jama.288.4.455 · Cited by 1,232
Naghavi, M., Falk, E., Hecht, H. S., Jamieson, M. J., Kaul, S., Berman, D., Fayad, Z., Budoff, M. J., Rumberger, J., Naqvi, T. Z., et al. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.03.002 · Cited by 635
Akosah, K. O., Schaper, A., Cogbill, C., & Schoenfeld, P. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00187-6 · Cited by 351
Genetic risk factors associated with lipid-lowering drug-induced myopathies
Vladutiu, G. D., Simmons, Z., Isackson, P. J., Tarnopolsky, M., Peltier, W. L., Barboi, A. C., Sripathi, N., Wortmann, R. L., & Phillips, P. S. (2006) · Muscle & Nerve · doi:10.1002/mus.20567 · Cited by 253
CD31+ T cells, endothelial function and cardiovascular risk
Weil, B. R., Kushner, E. J., Diehl, K. J., Greiner, J. J., Stauffer, B. L., & DeSouza, C. A. (2011) · Heart, Lung and Circulation · doi:10.1016/j.hlc.2011.06.003 · Cited by 18
Metadata
- Authors
- Fedder, D. O., Koro, C. E., & L’Italien, G. J.
- Venue
- Circulation
- Published
- 2002-01-15
- Volume
- 105
- Issue
- 2
- Pages
- 152-156
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2137025912
- Cited by
- 158
- References
- 4
- FWCI
- 19.06
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: New National Cholesterol Education Program III Guidelines for Primary Prevention Lipid-Lowering Drug Therapy: Projected Impact on the Size, Sex, and Age Distribution of the Treatment-Eligible Population. https://app.cochat.ai/papers/10.1161/hc0202.101971
- The paper
- Fedder, D. O., Koro, C. E., & L’Italien, G. J. (2002). New National Cholesterol Education Program III Guidelines for Primary Prevention Lipid-Lowering Drug Therapy: Projected Impact on the Size, Sex, and Age Distribution of the Treatment-Eligible Population. Circulation. https://doi.org/10.1161/hc0202.101971
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.